Gemcitabine versus cisplatin and gemcitabine in first-line treatment of patients with advanced non-small cell lung cancer in poor physical condition (performance status 2)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

28 Mar 2017 Biomarkers information updated
31 May 2013 Status changed from active, no longer recruiting to discontinued, according to the abstract presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
31 May 2013 Primary endpoint 'Overall-survival-duration' has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com